Artiva Biotherapeutics, Inc. (ARTV) Stock Analysis
Artiva is a high-risk, high-upside clinical biotech seeking to turn off-the-shelf NK-cell therapy into a scalable outpatient alternative to autoimmune CAR-T.
Overview
Artiva Biotherapeutics is a pre-revenue clinical-stage biotech developing allogeneic, off-the-shelf NK-cell therapies for severe B-cell-driven autoimmune diseases. Its lead asset, AlloNK, is paired with anti-CD20 antibodies such as rituximab to deliver deep B-cell depletion and immune-system reset. Early data show outpatient feasibility, strong B-cell depletion, and no reported CRS or ICANS, positioning AlloNK as a potentially scalable alternative to costly autologous CAR-T therapies. The company remains dependent on equity financing but has a transformed runway after a major 2026 capital raise.